16,137 Shares in LivaNova PLC $LIVN Bought by Gibbs Wealth Management

Gibbs Wealth Management bought a new position in LivaNova PLC (NASDAQ:LIVN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,137 shares of the company’s stock, valued at approximately $1,026,000.

A number of other hedge funds also recently added to or reduced their stakes in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after acquiring an additional 1,360 shares during the period. Goldman Sachs Group Inc. grew its position in shares of LivaNova by 4.6% during the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after acquiring an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares during the period. Intech Investment Management LLC increased its holdings in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio bought a new stake in LivaNova in the 1st quarter valued at about $130,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Freedom Capital raised shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Barclays raised their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Robert W. Baird cut their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. KeyCorp boosted their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Zacks Research upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $81.38.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $78.19 on Friday. The stock has a fifty day moving average price of $78.31 and a two-hundred day moving average price of $69.54. The firm has a market cap of $4.30 billion, a P/E ratio of 40.10 and a beta of 0.86. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $85.27. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Research analysts forecast that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.35% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.